My Last Warning on These AI Data Center Stocks. (3 to Buy, 2 You'll Regret)
2 extracted signals · 0 resolved · 2 still active
MarketBeatIndependent analyst profile- Source published
- 07 Aug 2026, 22:30 UTC
- Recorded by Tahlil Plus
- 08 Aug 2026, 00:36 UTC
AI-generated source summary
The analysis covers three stocks: CRWV, NBIS, and HIVE, all of which are presented as AI infrastructure plays. CRWV is currently trading at $90.64, with a target of $138.32 and a failure bound at $75.00, suggesting a bullish outlook despite recent bearish price action. NBIS is priced at $187.97, with a target of $289.88 and a failure bound at $150.00, also indicating a bullish bias. HIVE, trading at $3.98, has a significantly higher potential target of $50.72 with a failure bound at $2.42, also suggesting a bullish long-term view. The reasoning behind these picks is tied to the broader AI infrastructure build-out and the companies' ability to capitalize on this trend. While CRWV and NBIS have experienced recent downturns, the analysis suggests they are poised for a recovery and growth, supported by their fundamental positioning in the AI sector. HIVE's transition from Bitcoin mining to AI infrastructure is highlighted as a key driver for its potential upside.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.